A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer

PHASE3

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped BeiGene and Celgene Corporation terminated the parties' global collaboration for the compound, pending the acquisition of Celgene by Bristol Myers Squibb

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Tislelizumab
DRUG: Concurrent chemoradiotherapy (cCRT)
OTHER: Placebo

Sponsor

Celgene

Collaborators

[object Object]